Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
Tax Provision
Halozyme Therapeutics Inc
Tax Provision Peer Comparison
Competitive Tax Provision Analysis
Latest Figures & CAGR of Competitors
Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Tax Provision
-$73.3m
|
CAGR 3-Years
-427%
|
CAGR 5-Years
-200%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$617m
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$582m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$760.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$184.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
6%
|
See Also
What is Halozyme Therapeutics Inc's Tax Provision?
Tax Provision
-73.3m
USD
Based on the financial report for Mar 31, 2024, Halozyme Therapeutics Inc's Tax Provision amounts to -73.3m USD.
What is Halozyme Therapeutics Inc's Tax Provision growth rate?
Tax Provision CAGR 5Y
-200%
Over the last year, the Tax Provision growth was -63%. The average annual Tax Provision growth rates for Halozyme Therapeutics Inc have been -427% over the past three years , -200% over the past five years .